<DOC>
	<DOCNO>NCT01869114</DOCNO>
	<brief_summary>This phase II trial study well sirolimus azacitidine work treat patient high-risk myelodysplastic syndrome recurrent acute myeloid leukemia . Sirolimus may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , azacitidine , work different way stop growth cancer cell , either kill cell stop dividing . Sirolimus azacitidine may kill cancer cell .</brief_summary>
	<brief_title>Sirolimus Azacitidine Treating Patients With High Risk Myelodysplastic Syndrome Acute Myeloid Leukemia That Recurrent Not Eligible Intensive Chemotherapy</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : I . To characterize rate response azacitidine sirolimus adult high-risk myelodysplastic syndrome ( MDS ) , relapse refractory acute myeloid leukemia ( AML ) unable unwilling tolerate high dose chemotherapy . SECONDARY OBJECTIVES : I . To determine pharmacodynamic effect sirolimus inhibition mammalian target rapamycin ( mTOR ) signal adults high-risk MDS , relapse refractory AML unable unwilling tolerate high dose chemotherapy . II . To determine safety tolerability sirolimus azacitidine adult high-risk MDS , relapse refractory AML unable unwilling tolerate high dose chemotherapy . III . To determine progression free survival overall survival adult high-risk MDS , relapse refractory AML unable unwilling tolerate high dose chemotherapy . IV . To determine quality life patient improve combination azacitidine sirolimus compare historical control azacitidine alone . OUTLINE : Patients receive sirolimus orally ( PO ) day 1-10 1-12 azacitidine intravenously ( IV ) day 4-8 , 11 , 12 day 4-10 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Patients must diagnosis one following : MDS ( Arm A ) : Highrisk MDS define : &gt; 5 % blast bone marrow and/or follow cytogenetic category : presence inv ( 3 ) /t ( 3q ) /del ( 3q ) , 7/del ( 7q ) , complex cytogenetics ( 3 abnormality ) AML ( Arm B ) : Relapsed/refractory/unable tolerate conventional chemotherapy MDS AML BUT prior therapy Azacitibine ( Arm C ) : Patients meet criterion either Arm A Arm B treat currently treat Azacitibine 2 . Patients must ≥ 18 year old 3 . Patients must ECOG performance status &lt; = 2 ( see Attachment 1 ) . 4 . Patients must life expectancy least 4 week . 5 . Patients must able consume oral medication . 6 . Patients must complete radiotherapy four week prior study entry , 02 week local palliative XRT ( small port ) . 7 . Patients must recover toxic effect prior chemotherapy &lt; Grade 2 ( except alopecia ) . 8 . Required initial laboratory value : Creatinine≤ 2.0mg/dL ; total direct bilirubin ≤ 1.5mg/dL ( due leukemia know Gilbert 's Syndrome ) ; ( document treat physician ) SGPT ( ALT ) ≤ 3xULN ; glucose &lt; 200 mg/dL , negative pregnancy test woman childbearing potential . 9 . Patients must able sign consent willing able comply schedule visit , treatment plan laboratory testing . 10 . Patients may prior stem cell transplant ( autologous allogeneic ) , however may active GvHD , immunosuppression 1 . Patients must receive chemotherapy agent ( except Hydroxyurea ) Intrathecal ARAC intrathecal methotrexate permissible ( systemic isolated central nervous system ) . Patients receive 3 prior line therapy hematologic malignancy . Patients meet study criterion either previously treat currently undergo treatment azacitibine shall evaluate Arm C 2 . Patients must receive growth factor . 3 . Patients current second malignancy require systemic therapy , nonmelanoma skin cancer , eligible . If patient prior second malignancy currently require active treatment , patient consider eligible . 4 . Patients uncontrolled high blood pressure , unstable angina , symptomatic congestive heart failure , myocardial infarction within past 6 month serious uncontrolled cardiac arrhythmia eligible . 5 . Patients may take follow medication study , consider eligible medication discontinue 72 hr prior first dose Sirolimus : Carbamazepine ( e.g . Tegretol ) Rifabutin ( e.g . Mycobutin ) Rifampin ( e.g . Rifadin ) Rifapentine ( e.g . Priftin ) St. John 's Wort may decrease effect sirolimus decrease amount sirolimus body Clarithromycin ( e.g . Biaxin ) Cyclosporin e.g . ( Neoral Sandimmune ) Diltiazem ( e.g . Cardizem ) Erythromycin ( e.g . AkneMycin , EryTab ) Itraconazole ( e.g . Sporanox ) Fluconazole ( e.g . Diflucan ) Ketoconazole ( e.g . Nizoral ) Telithromycin ( e.g . Ketek ) Verapamil ( e.g . Calan SR , Isoptin , Verelan ) Voriconazole ( e.g . VFEND ) May increase effect sirolimus increase amount medicine body . Can take 72 hour last dose Sirolimus Tacrolimus ( e.g . Prograf ) May cause liver transplant rejection serious side effect patient sirolimus . 6 . Patients know HIV positivity AIDSrelated illness eligible . 7 . Patients severe concurrent disease judgment investigator would make patient inappropriate entry study ineligible . 8 . Patients must receive investigational agent within 21days study entry . 9 . Patients must pregnant breastfeeding . Pregnancy test must obtain female childbearing potential . Pregnant lactate patient ineligible study due unknown human fetal teratogenic toxicity rapamycin . Males female reproductive age may participate unless agree use effective contraceptive method . 10 . Patients uncontrolled infection eligible . Patients must active infection control . Fungal disease must stable least 2 week study entry . Patients bacteremia must document negative blood culture prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>